The Sanguine Difference

By simplifying the donation process, we have built a highly-engaged group of donors for minimally-invasive biospecimens.

Our Success In Numbers

2000+

Completed

Studies

93%

Delivered to Plan

25+

Top Pharma
Clients

100+

Nonprofit Organization Partnerships

70,000+

Donor Community

How the Legacy Indirect Model Stacks Up Against Ours

 

   

  • Donor Access and Engagement
  • Strategies for reach, recruitment, retention
  • Geographic and demographic diversity
  • Diversity of disease states
  • Donor Centricity
  • Study Design Capabilities
  • Sample collection
  • Participant retention
    (longitudinal studies)
  • Donor Data
  • Post-collection processing
  • Clinically Relevant Annotated Specimens
  • Sample integrity
  • Biospecimen and data owner
  • Longitudinal sampling
  • Simultaneous collection of multiple specimen types
  • Large volume collection (≤180 mL)
  • Patient-reported outcomes data
    (PRO, ePRO)
  • Same-day sample collection and delivery
  • Integrated FHIR and C-CDA electronic health record data
  • Specialty Biospecimen Collection
  • Leukopaks (leukocyte-enriched apheresis products)
  • Healthy specimens collected at client’s facilities

Direct Donor Access
Sanguine Model

  • Donor Access and Engagement
  • Strategies for reach, recruitment, retention Mobile, virtual, flexible
  • Geographic and demographic diversity Nationwide, urban or rural
  • Diversity of disease states Broad, multi-faceted
  • Donor Centricity Engaged homegrown communities
  • Study Design Capabilities
  • Sample collection Prospective
  • Participant retention
    (longitudinal studies)         High retention rates >95%
  • Donor Data FHIR and C-CDA electronic health records, demographics, ability to add surveys, questionnaires, and outcomes
  • Post-collection processing Customize parameters and procedures
  • Clinically Relevant Annotated Specimens
  • Sample integrity
  • Biospecimen and data owner
  • Longitudinal sampling
  • Simultaneous collection of multiple specimen types
  • Large volume collection (≤180 mL)
  • Patient-reported outcomes data
    (PRO, ePRO)
  • Same-day sample collection and delivery
  • Integrated FHIR and C-CDA electronic health record data
  • Specialty Biospecimen Collection
  • Leukopaks (leukocyte-enriched apheresis products)
  • Healthy specimens collected at client’s facilities

Indirect Donor Access
Biobanks, Others

  • Donor Access and Engagement
  • Strategies for reach, recruitment, retention Confined, brick and mortar
  • Geographic and demographic diversity Limited by access to medical facility
  • Diversity of disease states Typically oncology-focused
  • Donor Centricity Third-party mediated, transactional
  • Study Design Capabilities
  • Sample collection Retrospective
  • Participant retention
    (longitudinal studies)         Low or no retention
  • Donor Data Often limited to demographics or possibly medical records
  • Post-collection processing Limited to how specimens were initially collected
  • Clinically Relevant Annotated Specimens
  • Sample integrity
  • Biospecimen and data owner
  • Longitudinal sampling
  • Simultaneous collection of multiple specimen types
  • Large volume collection (≤180 mL)
  • Patient-reported outcomes data
    (PRO, ePRO)
  • Same-day sample collection and delivery
  • Integrated FHIR and C-CDA electronic health record data
  • Specialty Biospecimen Collection
  • Leukopaks (leukocyte-enriched apheresis products) Specialty vendors
  • Healthy specimens collected at client’s facilities
Young chemist working in the lab

Access challenging, hard-to-collect samples

Sanguine's unique donor-centric approach to biospecimen collection gives researchers access to rare populations and complex study designs such as event-based collection, longitudinal collections, and more.

Are you a researcher?

Find out how Sanguine can accelerate your study.

Request a Quote